NEWS

    News dated April 1, 2026: The U.S. FDA officially approved the launch of Eli Lilly’s Orforglipron under the brand name Foundayo. It is the II orally administered GLP-1 weight-loss drug approved worldwide, marking that the global weight management market is officially stepping in...

  Xanomeline, an old drug   Xanomeline is an old drug. Back in the 1990s, Novo Nordisk and Eli Lilly carried out a large number of clinical trials on it, mainly for the indication of Alzheimer's disease (AD). Regrettably, the trials were forced to terminate in 1998 owing to its notable ga...

    On January 30, 2025, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) 50 mg oral tablets — a first-in-class non-opioid analgesic — for the treatment of moderate to severe acute pain in adults.   Pain is a common medical condition, and reliev...

    On the evening of March 18, 2026, Johnson & Johnson announced that its oral peptide drug Icotrokinra (brand name: ICOTYDE) has been approved by the FDA for the treatment of moderate to severe plaque psoriasis (PsO) in adolescents aged 12 years and older and adults. It is the world...

                                        On June 18, 2025, Gilead Sciences officially announced via its official website that Yeztugo® (Lenacapavir) has become the first and only FDA-approved HIV p...

      On March 24, 2026, a major breakthrough was achieved in the treatment of chronic spontaneous urticaria (CSU). Remibrutinib, a novel oral targeted drug, was officially dispensed its first prescription in China.    The first prescription was issued in Tianjin, China by...

  Developed by Pfizer, lorlatinib (brand name: Lorbrena®) is a third-generation dual-target tyrosine kinase inhibitor targeting ALK and ROS1. It is specially indicated for patients with locally advanced or metastatic ALK-positive non-small cell lung cancer.   Lorlatinib approval for ma...

    On March 30, 2026, Merck (MSD) announced the results of the Phase III CORALreef AddOn study of MK-0616 Enlicitide. This is an active comparator trial designed to evaluate the efficacy and safety of enlicitide decanoate versus other oral non-statin lipid-lowering therapies, when added...